ArticleEuropean journal of medical research2026
TMPRSS2 is dispensable for lethal SARS-CoV-2 BA.5 infection in humanized hACE2 golden hamsters.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV-2) can specifically bind to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface via the corresponding spike (S) protein, facilitating the entry of the virus. ACE2 is highly expressed in alveolar type II cells, respiratory epithelial cells, and various other tissues, which provides favorable conditions for the transmission of SARS-CoV-2. TMPRSS2, a transmembrane serine protease widely distributed in the respiratory tract and digestive tract, cleaves the receptor-binding domain (RBD) and S1/S2 subunit of the SARS-CoV-2 spike protein. The protein cleavage activates the virus and enhances its binding to ACE2. This study reported for the first time that Tmprss2 deficiency reduces susceptibility to SARS-CoV-2 in golden hamsters. Infection experiments were conducted with three SARS-CoV-2 variants (Beta, BA.5, and XBB). The findings revealed that compared to the wild-type control, TMPRSS2 knockout in hamsters resulted in lower viral titers in the lungs and reduced pathological damage. Our results showed that Tmprss2 KO;H11-K18-hACE2 hamsters succumbed to infection with SARS-CoV-2 (BA.5 strain) by day 5 post-inoculation, similar to H11-K18-hACE2 hamsters. These findings indicated that SARS-CoV-2-induced mortality in humanized hACE2 hamsters occurs independently of TMPRSS2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.